RAGE and ACE2 shedding as therapeutic targets in diabetes and cardiovascular disease

RAGE 和 ACE2 脱落作为糖尿病和心血管疾病的治疗靶点

• 批准号: nhmrc : GNT1127526
• 负责人: Dr Christos Tikellis
• 金额: $ 74.84万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/rage-ace2-shedding-cardiovascular-disease/1347629
• 关键词: RAGE; ACE2; shedding; therapeutic; targets

We have previously demonstrated the pivotal role of two shed proteins, Receptor for Advanced Glycation End-products (RAGE) and Angiotensin Converting Enzyme Receptor 2 (ACE2) in heart disease and diabetic complications. In this project, we will use a novel technologies to modify shedding of these proteins from the cell surface and alter their ability to cause disease.

我们之前已经证明了两种脱落蛋白，晚期糖基化终产物受体（RAGE）和血管紧张素转换酶受体2 （ACE2）在心脏病和糖尿病并发症中的关键作用。在这个项目中，我们将使用一种新技术来修饰这些蛋白质从细胞表面脱落并改变它们引起疾病的能力。